Tislelizumab is greenlit as a first-line treatment in combination with certain drugs in non-small cell lung cancer.

This new drug belongs to a class of immunotherapy agents and is called Tislelizumab-jsgr (brand name Tevimbra). If you or a ...

Tislelizumab received approval from the European Commission for advanced or metastatic ESCC after prior chemotherapy in 2023 and a positive opinion from the Committee for Medicinal Products for ...

EU regulators have approved BeiGene's (BGNE) tislelizumab for the treatment of certain types of non-small cell lung cancer.

By Chris Wack BeiGene shares were up 7% to $139.39 after the company said the European Commission has approved tislelizumab as a treatment for non-small ...

The EC has approved Tevimbra as first-line treatment in combination with carboplatin and either paclitaxel or nab-paclitaxel ...

Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-naïve and relapsed NSCLC Decision represents tislelizumab’s ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BASEL, Switzerland - The European Commission (EC) has granted approval to tislelizumab for the treatment of non-small cell lung cancer (NSCLC) in three different settings, marking the second ...